Picture of Jaguar Health logo

JAGX Jaguar Health Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+3.83%
3m-60.61%
6m-78.72%
1yr-95.17%
Volume Change (%)
10d/3m+102.91%
Price vs... (%)
52w High-94.34%
50d MA-17.2%
200d MA-76.93%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-89.06%
Return on Equity-1586.22%
Operating Margin-273.51%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Jaguar Health EPS forecast chart

Profile Summary

Jaguar Health, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing plant-based, sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. It operates through two segments: human health and animal health. Human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. Its subsidiary includes Napo Pharmaceuticals, Inc., which focuses on developing and commercializing plant-based human pharmaceuticals.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
June 6th, 2013
Public Since
May 13th, 2015
No. of Shareholders
18
No. of Employees
60
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
233,423,917

JAGX Share Price Performance

Upcoming Events for JAGX

Q4 2023 Jaguar Health Inc Earnings Release

Jaguar Health Inc Extraordinary Shareholders Meeting

Q1 2024 Jaguar Health Inc Earnings Release

Jaguar Health Inc Annual Shareholders Meeting

Q2 2024 Jaguar Health Inc Earnings Release

Similar to JAGX

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acesis Holdings logo

Acesis Holdings

us flag iconNASDAQ Capital Market

Picture of Achieve Life Sciences logo

Achieve Life Sciences

us flag iconNASDAQ Capital Market

FAQ